Thank you. We will cite this papers. 

Best

On Dec 14, 2020, at 4:06 PM, Vladimir Kiselev <vk6@sanger.ac.uk> wrote:

Hi Avinash (Jonah and Ni are cc:ed for confirmation),
 
I believe for the patient part of covid19cellatlas you should reference this preprint:
https://www.medrxiv.org/content/10.1101/2020.11.20.20227355v1 [medrxiv.org]
 
And for the healthy part of the atlas you should reference this article:
https://www.nature.com/articles/s41591-020-0868-6
 
Hope this helps,
Cheers,
Vlad
 
--
Vladimir Kiselev
 
CellGen Informatics Team Leader
Wellcome Sanger Institute
Wellcome Genome Campus
Hinxton, Cambridge, CB10 1SA
Phone: +44 (0) 1223 496850
Message: Mattermost or Slack
Web: https://wikiselev.github.io
 
 
From: Avinash Sahu <asahu@ds.dfci.harvard.edu>
Date: Monday, 14 December 2020 at 10:07
To: "cv19caingest@sanger.ac.uk" <cv19caingest@sanger.ac.uk>
Subject: [Cv19caingest] CV19 cell atlas publication policy [EXT]
 
Dear all, 
 
We, computational scientists, are developing new statistical methods for the analysis of single-cell data. The application of these methods to COVID-19 data has revealed novel findings in terms of its biology, which would also impact its treatment. We are gearing towards the submission of these findings. Could you let us know regarding the policy of publication manuscripts that leverage COVID19 cell atlas data? We will be happy to accommodate researchers who had generated the data as co-authors in the manuscript as deemed necessary. 
 

Avinash Sahu
Research Fellow
asahu@ds.dfci.harvard.edu 
https://connects.catalyst.harvard.edu/Profiles/display/Person/165880 [connects.catalyst.harvard.edu]

<image001.png>


-- The Wellcome Sanger Institute is operated by Genome Research Limited, a charity registered in England with number 1021457 and a company registered in England with number 2742969, whose registered office is 215 Euston Road, London, NW1 2BE.